A New Paradigm of Bispecific Antibodies in Clinical Management of Gastrointestinal Cancers.

Oncol Res · 2026 · PMC13292066 · PMID 42358825

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

Another Phase Ib/II trial ( NCT05964543 ) of Q-1802 in combination with chemotherapy (XELOX) in patients with treatment-naive advanced gastric/gastroesophageal junction cancer revealed a significant trend: among patients with high CLDN18.2 expression (moderate-to-strong membranous staining in ≥70% of tumor cells), the ORR was 70.3% (26/37).

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.